Get the Stockscreener App
16.07
7.11%
-1.23
Bausch Lomb Corp stock is traded at $16.07, with a volume of 2.93M.
It is down -7.11% in the last 24 hours and down -6.84% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$17.30
Open:
$16.83
24h Volume:
2.93M
Relative Volume:
4.88
Market Cap:
$5.74B
Revenue:
$5.21B
Net Income/Loss:
$-211.00M
P/E Ratio:
-26.01
EPS:
-0.6179
Net Cash Flow:
$861.30K
1W Performance:
-6.41%
1M Performance:
-6.84%
6M Performance:
-2.55%
1Y Performance:
+12.22%
1-Day Range:
$15.47
$16.84
1-Week Range:
$15.47
$17.50
52-Week Range:
$13.77
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, RMD, MDLN, ALC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
16.07 | 5.74B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
427.64 | 151.08B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
188.89 | 51.45B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
234.60 | 32.99B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.76 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
64.35 | 31.11B | 10.63B | 819.00M | 1.59B | 1.6577 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-26 | Initiated | Barclays | Overweight |
| Sep-09-26 | Initiated | Leerink Partners | Outperform |
| Jul-28-26 | Initiated | UBS | Buy |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-01-25 | Initiated | Goldman | Neutral |
| May-02-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Bausch + Lomb CEO Saunders departs, Chairman Appio named interim chief - Reuters
Thomas J. Appio Named Interim CEO of Bausch + Lomb as Brent Saunders Departs - VisionMonday.com
What Could Bausch Health (TSX:BHC) Reveal in Its Next Results? - Kalkine Media
Bausch + Lomb names Appio interim CEO as Saunders departs - StreetInsider
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance - Yahoo Finance
Bausch Health's CEO now also leads Bausch + Lomb as interim CEO. - Stock Titan
Barclays Initiates Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $24 - Moomoo
RBC Capital Remains a Buy on Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Bausch + Lomb's Dry Eye Disease Prescription Momentum Builds, Forex Turns as Modest Headwind in Q3, RBC Says - marketscreener.com
Barclays Reaffirms Their Buy Rating on Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Bausch & Lomb Initiated at Overweight by Barclays - Moomoo
Bausch + Lomb stock gets BL1243 update after FDA meeting - AD HOC NEWS
Why Is SeeLyra Approval Important For Bausch + Lomb (TSX:BLCO)? - Kalkine Media
Bausch + Lomb to Advance Eye Disease Treatment Following FDA Meeting - marketscreener.com
A possible medicine to take by mouth for macular degeneration is planned for 2027 testing - Stock Titan
Bausch + Lomb Sets Date for Third-Quarter 2026 Earnings Release and Investor Call - The Globe and Mail
Bausch + Lomb Corporation (TSX:BLCO): Can Vision Care Grow? - Kalkine Media
Bausch + Lomb Corporation - Baystreet.ca
Stocks in play: Bausch + Lomb Corporation - Yahoo! Finance Canada
Bausch + Lomb will give a business update in a live webcast at 8 a.m. Oct. 28 - Stock Titan
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28 - Business Wire
Bausch + Lomb : Review Article in Expert Review of Ophthalmology Provides a Blueprint for Patient-Centric Approaches to Dry Eye Management - marketscreener.com
Bausch + Lomb (BLCO) Stock Price, News & Analysis - MarketBeat
Bausch + Lomb (BLCO) Earnings Date and Reports 2026 - MarketBeat
Top Bausch + Lomb (BLCO) Competitors 2026 - MarketBeat
Bausch + Lomb Corporation (BLCO.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bausch + Lomb (TSX:BLCO): What Does SeeLyra Approval Mean? - Kalkine Media
Bausch + Lomb stock reports 9.1 percent revenue growth - AD HOC NEWS
Veterinary Ophthalmology Equipment Market by Product, Animal Type, Application, End User, Region Report Forecasts Market to Reach USD 0.83 Billion by 2031, Growing at a 7.7% CAGR - GlobeNewswire Inc.
Bausch Health Companies Inc. (BHC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bausch + Lomb Corporation (BLCO) Stock Analysis: Potential 12.99% Upside Beckons Investors in the Healthcare Sector - DirectorsTalk Interviews
Bausch + Lomb Q2 2026 Earnings: EPS Edges Past Estimates as Stock Slips SlightlyEarnings Forecast Report - careplusvn.com
Robinson Pharma, Inc. Receives "Above and Beyond" Supplier Award from Bausch + Lomb for September 2026 - Yahoo Finance
Bausch + Lomb's SeeLyra femtosecond laser earns European CE mark - Ophthalmology Times
Bausch + Lomb receives CE Mark for SeeLyra laser - grafa.com
Stocks in play: Bausch + Lomb Corporation - The Globe and Mail
Bausch + Lomb receives CE Mark for SeeLyra femtosecond laser - investing.com
Bausch + Lomb receives CE Mark for SeeLyra femtosecond laser By Investing.com - Investing.com India
Bausch + Lomb receives CE Mark for SeeLyra femtosecond laser By Investing.com - Investing.com UK
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser - Eagle-Tribune
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser - Business Wire
Bausch + Lomb Appoints Rob Nadler as SVP, Business Development and Corporate Strategy - VisionMonday.com
The Technical Signals Behind (BLCO) That Institutions Follow - Stock Traders Daily
Leerink Partners Initiates Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $24 - Moomoo
(BLCO) Advanced Trading Insights (BLCO:CA) - Stock Traders Daily
Bausch + Lomb Corporation (BLCO) Investor Outlook: Eyeing a 3.24% Upside Amid Diverse Global Operations - DirectorsTalk Interviews
Bausch + Lomb stock rises on survey-driven dry eye focus - AD HOC NEWS
Why Bausch + Lomb Corp stock is gaining today - Wealth Awesome
Bausch + Lomb study shows enVista Aspire lenses improve vision By Investing.com - Investing.com Canada
Bausch + Lomb study shows enVista Aspire lenses improve vision - investing.com
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bausch Lomb Corp Stock (BLCO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Munsch Frederick | Former Officer |
Aug 10 '26 |
Proposed Sale |
16.78 |
52,900 |
887,885 |
0 |
| Munsch Frederick | SVP, Controller and CAO |
Aug 10 '26 |
Sale |
16.78 |
52,900 |
887,662 |
45,831 |
| VON ESCHENBACH ANDREW C. | Former Director |
Aug 07 '26 |
Proposed Sale |
16.58 |
6,059 |
100,430 |
0 |
| VON ESCHENBACH ANDREW C. | Director |
Aug 07 '26 |
Sale |
16.58 |
6,059 |
100,458 |
63,733 |
| VON ESCHENBACH ANDREW C. | Director |
Aug 06 '26 |
Sale |
16.50 |
12,500 |
206,250 |
69,792 |
| VON ESCHENBACH ANDREW C. | Former Director |
Aug 06 '26 |
Proposed Sale |
16.50 |
12,500 |
206,193 |
0 |
| SAUNDERS BRENT L | CEO and Chairman of the Board |
Mar 06 '26 |
Buy |
17.14 |
14,700 |
251,958 |
966,575 |
| Bailey A Robert D | EVP & Chief Legal Officer |
Mar 06 '26 |
Buy |
17.15 |
14,600 |
250,332 |
231,890 |
| Eldessouky Sam | EVP and CFO |
Mar 06 '26 |
Buy |
17.13 |
4,000 |
68,520 |
403,130 |
| Ross Thomas W. Sr. | Director |
Mar 03 '26 |
Buy |
17.68 |
4,500 |
79,556 |
64,891 |
2.91%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):